SNuRM^® Profiling

Selective Cofactor recruitment by a ligand-stimulated Nuclear Receptor is the major reason for compound- and tissue-selective gene regulation or pharmacological effects.

Phenex is the pioneer in performing SNuRM® analyses in the sense of determining compound-dependent differences in Cofactor recruitment in different assays formats. Phenex has established the following modules for the qualitative and quantitative assessment of Cofactor selectivity:

- a fully automated Yeast-2-Hybrid profiling system
- a Mammalian-2-Hybrid system
- a NR Cofactor peptide FRET assay system
- a qRT-PCR (Taqman® based) module for quantification of individual gene expression

Figure: Phenex SNuRM® platform

Quantitative differences in Cofactor recruitment which can be determined using our SNuRM® platform translate in vivo into differential gene response and selective pharmacological effects. It is the goal of a SNuRM® project to

• a. bin the existing panel of ligands at a given Nuclear Receptor into different response groups, and
• b. ideally identify those "surrogate marker" Cofactors whose recruitment is predictive for a certain gene or even pharmacological response

If such a correlation b. can be successfully established, these "indicative" Cofactors can be used in respective assays (Mammalian-2-Hybrid or FRET) to guide high content screening or lead optimisation towards more selective NR ligands with more desired properties.

If you want to learn more about our SNuRM® Profiling capabilities, please contact us under
info@phenex-pharma.com.

Further available information:
- General Information on the SNuRM® Approach
- More information about the Yeast-2-Hybrid system NR
- More information about the NR Cofactor peptide FRET assay system